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Abstract
Glutamate clearance by astrocytes is an essential part of normal excitatory neurotransmission. 
Failure to adapt or maintain low levels of glutamate in the central nervous system is associated 
with multiple acute and chronic neurodegenerative diseases. The primary excitatory amino acid 
transporters in human astrocytes are EAAT1 and EAAT2 (GLAST and GLT-1 respectively in 
rodents). While the inhibition of calcium/calmodulin-dependent kinase (CaMKII), a ubiquitously-
expressed serine/threonine protein kinase, results in diminished glutamate uptake in cultured 
primary rodent astrocytes (Ashpole et al. 2013), the molecular mechanism underlying this 
regulation is unknown. Here, we use a heterologous expression model to explore CaMKII 
regulation of EAAT1 and EAAT2. In transiently transfected HEK293T cells, pharmacological 
inhibition of CaMKII (using KN-93 or tat-CN21) reduces [3H]-glutamate uptake in EAAT1 
without altering EAAT2 mediated glutamate uptake. While overexpressing the Thr287Asp mutant 
to enhance autonomous CaMKII activity had no effect on either EAAT1 or EAAT2 mediated 
glutamate uptake, overexpressing a dominant-negative version of CaMKII (Asp136Asn) 
diminished EAAT1 glutamate uptake. SPOTS peptide arrays and recombinant GST-fusion proteins 
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of the intracellular N- and C-termini of EAAT1 identified two potential phosphorylation sites at 
residues Thr26 and Thr37 in the N-terminus. Introducing an Ala (a non-phospho mimetic) at 
Thr37 diminished EAAT1-mediated glutamate uptake, suggesting that the phosphorylation state of 
this residue is important for constitutive EAAT1 function. Our study is the first to identify a 
glutamate transporter as a direct CaMKII substrate and suggests that CaMKII signaling is a critical 
driver of constitutive glutamate uptake by EAAT1.
Graphical abstract
Pharmacological and genetic inhibition of the calcium/calmodulin-dependent protein kinase II 
(CaMKII) reduces excitatory amino acid transporter EAAT1 function without impacting EAAT2-
mediated glutamate uptake. We identify EAAT1 as a novel CaMKII substrate and Thr37 
phosphorylation as an important modulator of constitutive EAAT1 activity. These data support the 
hypothesis that CaMKII regulates glutamate homeostasis and that a loss of CaMKII signaling may 
exacerbate neuronal survival during excitotoxicity.
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Background
L-glutamate is the principal excitatory neurotransmitter in the central nervous system 
(Fonnum 1984). The ability of astrocytes to rapidly and efficiently clear synaptic glutamate 
is integral to physiological excitatory neurotransmission (Haydon & Carmignoto 2006, 
Rosenberg & Aizenman 1989). The excitatory amino acid transporters (EAAT) 1 and 2 
(GLAST and GLT-1 in rodents, respectively) mediate glutamate uptake by astrocytes (Storck 
et al. 1992, Pines et al. 1992). However, pathological dysregulation of these transporters has 
been associated with elevated extracellular glutamate in the brain (Yi & Hazell 2006), 
potentially contributing to neuronal dysfunction and death due to glutamate-induced 
excitotoxicity (Choi 1992, Olney & Sharpe 1969). In fact, compromised glutamate uptake by 
astrocytes has been implicated in a number of different neurodegenerative diseases, 
including ischemic stroke, amyotrophic lateral sclerosis, traumatic brain injury, and 
Alzheimer’s disease (Bruhn et al. 2000, Rothstein et al. 1992, van Landeghem et al. 2006, 
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Cassano et al. 2012). A better understanding of the complex mechanisms regulating 
glutamate uptake may be key to targeting the detrimental effects associated with aberrant 
glutamatergic neurotransmission.
The calcium/calmodulin-dependent kinase II (CaMKII) is a multifunctional serine/threonine 
protein kinase expressed in high levels in the brain where it regulates a number of cellular 
processes, including calcium homeostasis, excitability, neurotransmitter synthesis/release 
and neuronal plasticity (Robison 2014, Hudmon & Schulman 2002). During ischemic 
conditions, CaMKII initially activates, followed by rapid and persistent inactivation and 
aggregation (Waxham et al. 1996, Aronowski et al. 1992, Hudmon et al. 2005, Tao-Cheng et 
al. 2002, Dosemeci et al. 2000). Because the neuronal death observed in animal models of 
cerebral ischemia correlates with the extent of CaMKII inactivation (Hanson et al. 1994), a 
loss of CaMKII signaling may be an important driver of excitotoxicity (Ashpole et al. 
2012b). In fact, pharmacological inhibition of astrocytic CaMKII produces functional 
changes that would likely exacerbate the neurotoxic effects produced by excitotoxicity 
(Ashpole et al. 2013, Ashpole & Hudmon 2011, Ashpole et al. 2012b). Specifically, CaMKII 
inhibition in astrocytes results in dysregulated calcium homeostasis, release of the 
gliotransmitter ATP and reduced glutamate uptake (Ashpole et al. 2013); functional changes 
that could compromise neuronal survival (Ashpole et al. 2013). Astrocytes express multiple 
glutamate transporter subtypes (Rothstein et al. 1996, Kondo et al. 1995). Although a recent 
study described regulation of a GLT-1 splice variant by CaMKII through phosphorylation of 
a scaffolding protein (Underhill et al. 2015), it is unknown whether CaMKII may be 
functionally regulating one or both of the astrocytic glutamate transporters.
Our working hypothesis is that aberrant CaMKII activity produced by excitotoxic calcium 
signaling dysregulates astrocytic glutamate uptake. In order to address this question, we 
utilize peptide and small molecule inhibitors of CaMKII in combination with genetic 
manipulations via the over-expression of a dominant negative and a mutant autonomous 
form of CaMKII to identify mechanisms underlying EAAT regulation by CaMKII. Lastly, 
we explore the contribution that site-specific phosphorylation plays in the constitutive 
regulation of the EAAT1 transporter.
Experimental Procedures
Materials
Glutamic acid, glycine, polyethylenimine (PEI), poly-D-lysine (PDL) and DL-threo-β-
benzyoxyaspartate (TBOA) were purchased from Sigma. Vectashield Hard-Set mounting 
medium was obtained from Vector Laboratories (Burlingame, CA) while Prolong Gold 
Antifade with DAPI mounting media (Molecular Probes) was purchased from Thermo 
Fisher Scientific (Florence, KY). 2-Amino-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-7-
(naphthalen-1-yl)-5-oxo-4H-chromene-3-carbonitrile (UCPH-101) was obtained from 
Abcam. Tat-CN21 (YGRKKRRQRRKRPPKLGQIGRSKRVVIEDDR) and tat-CN21 Ala 
(YGRKKRRQRRKAPAKAAQAAASKRVVIEDDR) were synthesized by Biopeptide Co. 
Inc (San Diego, CA). KN-92 and KN-93 were purchased from EMD Millipore. 
Radiolabeled [3H]-glutamate was obtained from American Radiolabeled Chemicals and 
[γ-32P]-ATP was obtained from Perkin-Elmer.
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Astrocyte cultures
Cortical astrocytes were obtained from P1–P2 Sprague Dawley pups (male and female) 
according to approved Institutional Animal Care and Use Committees guidelines as 
described previously (McCarthy & de Vellis 1980, Ashpole et al. 2013). Dams were 
obtained from Envigo (Indianapolis, IN). Briefly, following enzymatic digestion and 
trituration, cells were re-suspended in growth media (DMEM containing 5% NuSerum, 
penicillin (10 units/mL), streptomycin (10 μg/mL) and B-27) and plated on PDL (50 μg/mL) 
coated dishes at a density of 2.5 million cells/mL. Upon reaching confluence, the plates were 
shaken to remove oligodendrocytes and microglia, and passaged using 0.05% trypsin 
(Invitrogen).
HEK293T cell culture
HEK293T cells were obtained from the American Type Culture Collection and cultured in 
DMEM, 10% heat inactivated fetal bovine serum, penicillin (10 units/mL), and streptomycin 
(10 μg/mL) at 37°C in 5% CO2 as previously described (Ashpole et al. 2012a, Hudmon et al. 
2005). Cells were passaged at confluency using 0.05% trypsin (Invitrogen).
cDNA constructs
cDNA for human EAAT1 and EAAT2 (obtained from Addgene in a pCMV5 backbone) was 
generously provided by Dr Susan Amara at the National Institute of Mental Health. Each 
transporter was sub-cloned into Creator-based acceptor vectors for mammalian expression 
with an N-terminal mCherry tag as previously described (Adler et al. 2013). For GST-fusion 
protein experiments, N- and C-termini of EAAT1 and EAAT2 and GluR1, a subunit of the 
AMPA receptor, were sub-cloned into PGEX vectors containing an N-terminal GST tag. The 
cDNA for human CaMKII (Ashpole et al. 2012a) was sub-cloned into a Creator-based 
vector with an N-terminal YFP tag.
Transient transfections
For CaMKII [γ-32P]-ATP activity assays and [3H]-glutamate uptake assays, HEK293T cells 
were transfected at 50–60% confluency with 2.5 μg cDNA and 2 mg/mL PEI in serum-free 
OptiMEM. Assays were performed 16–24h later, when cells were confluent. For imaging, 
HEK293T cells were transfected at 70–80% confluency with 6 μg cDNA and 2 mg/mL PEI 
in serum-free OptiMem in 100 mm tissue culture dishes. Cells were plated onto PDL (50 
μg/mL) coated glass coverslips 24 hours after transfection and processed (as described 
below).
Microscopy
Transfected HEK293T cells (for 24–48 hrs) were fixed in 4% paraformaldehyde in 0.1 M 
phosphate buffer, pH 7.4 for 10 minutes and washed 2X in cold PBS. Subsequently, 
coverslips were mounted in Vectashield Hard-Set mounting media or Prolong Gold Antifade 
with DAPI mounting media and fluorescence imaged in transfected cells using a Zeiss Axio 
Observer Z1 (10× objective or 63× oil objective). The fluorescent images were collected and 
analyzed using Axiovision 4 under DIC, red (Texas red;excit. 595 nm/emis. 620 nm) and 
green channels (FITC;excit. 490 nm/emis. 525 nm).
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CaMKII [γ-32P]-ATP Activity Assays
HEK293T cultures were washed in cold PBS, and lysed in 20 mM Tris pH 7.4, 200 mM 
NaCl, 0.1 mM EDTA, using a homemade protease inhibitor cocktail (1 mM AEBSF, 300 
nM Aprotinin, 2 μM E-64, 2 μM Leupeptin) as described previously (Ashpole et al. 2013). 
The lysate was sonicated briefly, vortexed, and incubated with 0.5% Triton-X 100 for 5–10 
minutes on ice. Total CaMKII activity was measured by incubating the lysate with 20 mM 
HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2, 100 μM ATP, 2 mM CaCl2, 5 μM 
calmodulin, 50 μM AC-2 (KKALRRQETVDAL) and [γ-32P]-ATP (3 μCi per reaction) for 5 
minutes at 30°C. Autonomous CaMKII activity (Ca2+/CaM-independent activity) was 
measured by incubating the lysate under similar conditions except 5 mM EGTA replaced 
Ca2+/CaM. To control for non-specific AC-2 phosphorylation in the lysate, reactions were 
incubated in the absence of AC-2. The linear range of the phosphorylation reactions 
extended >10 mins. A DC protein assay kit (Bio-Rad) was used to measure protein levels in 
the lysate using bovine serum albumin as a standard. CaMKII activity was normalized to 
total protein to account for variability in cell density or lysis.
[3H]-Glutamate Uptake Assays
Transfected HEK293T cells (with mCherry vector control, mCherry-EAAT1 or mCherry-
EAAT2) and cultured cortical astrocytes were pre-treated with pharmacological antagonists 
(10 μM UCPH-101, 10 μM TBOA or 10 μM DHK) to identify the contribution of specific 
transporters for 20 minutes at 37°C. Rat physiological saline (138 mM NaCl, 2.7 mM KCl, 
1.8 mM CaCl2, 1.06 mM MgCl2, 12.4 mM HEPES, pH 7.4, 5.6 mM glucose; final pH 
adjusted to 7.3) containing 0.1 μCi/ml [3H]-glutamate and 100 μM unlabeled glutamate was 
then applied to HEK293T cells for 20 min at 37°C. The cultures were then washed in cold 
PBS, lysed in lysis buffer (above) containing 1% Triton X-100, vortexed, incubated for 5 
min on ice, diluted in 8 ml RadSafe liquid scintillation cocktail (Beckman Coulter) and [3H] 
was quantified using a scintillation counter. A DC protein assay was performed as described 
above, and uptake was normalized to total protein.
Western Blotting
HEK293T cells were transfected, lysed, sonicated, and protein concentration was 
determined as described above. Lysate was re-suspended in LDS sample loading buffer 
containing β-mercaptoethanol (BME) and heated for 5 mins at 80°C before proteins (15–20 
μg) were separated using either a 10% Tris-Glycine gel or 4–12% Bis-Tris NuPAGE gel. 
Proteins were transferred onto a 0.2 μM nitrocellulose membrane and western blotting was 
performed using rabbit EAAT1 (Santa Cruz, 1:1000), rabbit EAAT2 (Abcam, 1:1000), and 
GAPDH (Cell Signaling, 1:1000) antibodies, followed by a DyLight800-labeled secondary 
antibody (Licor, 1:20000). Antibodies are fully annotated in Supplementary Table 2. 
Immunostaining was quantified using ImageJ software (National Institutes of Health).
Site-directed mutagenesis
Site-directed mutagenesis, performed as described by the manufacturer (Agilent 
Technologies), was used to introduce point mutations into the human cDNAs for δCaMKII 
or EAAT1. Mutations and their respective primers are annotated in Supplemental Table 1. 
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Double mutations were carried out sequentially. All mutations were verified by gene 
sequencing (Eurofins MWG Operon).
In Vitro SPOTs Phosphorylation Assay
15-amino acid long peptides spanning the intracellular regions of EAAT1 and EAAT2 (1–15, 
2–16, 3–17 etc.) were synthesized onto β-alanine derivatized cellulose membranes using the 
SPOTS synthesis method as described previously (Adler et al. 2013, Ashpole et al. 2012a). 
Following synthesis, the membrane was de-protected twice with a solution of trifluoroacetic 
acid containing 5% phenol and 2% triisopropylsilane. Next, the membrane was blocked with 
5% BSA in 50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, and 0.02% NP-40 for 30 
minutes followed by three washes in 100 mM Tris-HCl pH 7.4. A pre-reaction was 
performed in the presence of 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2, 0.5 
mM CaCl2, 5 μM CaM, 500 μM ATP and 500 nM recombinant purified human δCaMKII 
for 10 minutes on ice to autophosphorylate δCaMKII at Thr287 as described previously 
(Ashpole et al. 2012a). Membranes were subjected to a kinase phosphorylation assay in the 
presence of 50 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2, 0.2 mM CaCl2, 1 μM 
CaM, 0.2 mg/ml BSA, 1 mM DTT, 100 μM ATP, 6–12 μCi/ml [γ-32P]-ATP, and 5–10 nM 
δCaMKII. The reactions were incubated at room temperature for 4 minutes unless otherwise 
noted, terminated with three washes (100 mM sodium phosphate pH 7.0, 1 M NaCl, 10 mM 
EDTA) and dried as described previously (Ashpole et al. 2012a). The extent of radioactive 
phosphate incorporation was quantified using a Fujifilm phosphoimager and expressed as 
photostimulated luminescence (PSL/mm2) for a 1.5 mm × 1.5 mm circle using MultiGauge 
(Ver 3.1).
GST-fusion protein phosphorylation
GST-tagged intracellular N- and C- termini of EAAT1 and EAAT2, EAAT1 phosphorylation 
mutants, GluR1 and a GST vector control were expressed in BL-21 competent E.coli cells 
overnight at 16°C using 0.2 mM isopropyl 1-thio-β-D-galactopyranoside. Cells were 
centrifuged at 200 × g for 10 minutes, re-suspended in lysis buffer (described above) and 
passed through a microfluidizer three times to lyse cells. A supernatant was collected after 
centrifugation (8,000 × g for 10 mins) and snap-frozen for single use aliquots. GST-fusion 
proteins were bound to glutathione agarose in binding buffer (20 mM Tris pH 7.4, 200 mM 
NaCl, 1 mM EDTA, 0.1% Tween-20 containing protease inhibitor) tumbling for 1.5 hours at 
4°C. Beads were then washed three times in binding buffer to remove any unbound lysate. A 
pre-reaction was performed as describe above to activate and autophosphorylate human 
δCaMKII. GST-bound fusion proteins were then phosphorylated on the glutathione beads 
with 100 nM δCaMKII in reaction mix containing 20 mM HEPES pH 7.4, 100 mM NaCl, 
10 mM MgCl2, 0.25 mM CaCl2, 5 μM CaM, 10μM ATP, and 60 μCi/ml [γ-32P]-ATP for 30 
mins at room temperature. The reaction was quenched with three 500 mM EDTA washes, 
followed by addition of LDS with BME and followed by protein denaturation at 80°C. 
Coomassie-blue staining of the gel allowed for visualization of GST-fusions and protein 
quantification using ImageJ was used to normalize for differences in protein expression and 
GST-capture levels. CaMKII phosphorylation of GST fusion proteins was detected using a 
phosphoimager (Fujifilm) and quantified using MultiGauge software as described above.
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Statistical Analysis
SigmaPlot 12.5 was used to perform statistical analysis. A one-way ANOVA followed by a 
post hoc Dunnett’s test was used to compare differences between the means of each group. 
A p value of ≤0.05 was considered significant.
Results
As we have described previously, CN21, a potent peptide inhibitor (Vest et al. 2007) derived 
from the natural CaMKII inhibitor protein CaMKIIN (Chang et al. 1998) conjugated to the 
cell-penetrant motif, tat (Ashpole & Hudmon 2011, Vest et al. 2010), produced a significant 
reduction in [3H]-glutamate uptake in cultured cortical astrocytes (Supplementary Figure 
1A). Its inactive inhibitor, tat-CN21 Ala, used to verify the specificity of the active 
compound and off-target effects, did not alter glutamate uptake, thus recapitulating the 
finding that basal CaMKII signaling regulates glutamate uptake in rodent cortical astrocytes 
(Ashpole et al. 2013). We next determined the pharmacological signature of the glutamate 
transporters responsible for uptake in our cultured astrocytes. Consistent with previous 
studies showing that cultured cortical astrocytes obtained from post-natal pups primarily 
express GLAST (the rodent homolog of EAAT1) (Swanson et al. 1997, Gegelashvili et al. 
1997), we observed that GLAST is the predominant functional glutamate transporter under 
our culture conditions (Supplementary Figure 1B). While the Na+-dependent glutamate 
transporter inhibitor TBOA (Shimamoto et al. 2004) accounted for 82±1% of the [3H]-
glutamate uptake under these conditions, the specific EAAT1 inhibitor UCPH-101 (Erichsen 
et al. 2010) reduced glutamate uptake by 75±8%, whereas DHK, an EAAT2 specific 
inhibitor, accounted for 15±8% (Supplementary Figure 1B). Thus, because EAAT1 accounts 
for >91% of the TBOA sensitive glutamate uptake, it is likely that EAAT1 is regulated by 
CaMKII in astrocytes. However, because CaMKII inhibition may still contribute to reduced 
glutamate uptake via EAAT2 in cortical astrocytes, we developed a heterologous expression 
system capable of exploring CaMKII regulation of both EAAT1 and EAAT2 isoforms.
Because HEK293T cell lines have been previously used as a model system to study Na+-
dependent glutamate transporter regulation (Peacey et al. 2009, Berry et al. 2005, Dunlop et 
al. 1999), we transiently transfected the human astrocytic glutamate transporters EAAT1 or 
EAAT2 with an N-terminal mCherry fusion tag into these cells and observed similar 
transfection efficiencies for EAAT1 (46 ± 7%, Figure 1A) and EAAT2 (43 ± 9%, Figure 
1B); values comparable to the mCherry vector control (50 ± 5%). Western blot analysis 
indicates that unlike the untransfected cells, the transfected HEK293T cells produce robust 
EAAT1 and EAAT2 expression at the expected molecular weights for each fusion (Figures 1 
C and D). Finally, we evaluated the function of EAAT1 and EAAT2 in our heterologous 
expression system by measuring [3H]-glutamate uptake. When normalized to the control 
condition (mCherry only), ectopic expression of EAAT1 and EAAT2 produced a 3.08 
± 0.14-fold and 3.31 ± 0.32-fold increase in [3H]-glutamate uptake respectively (Figure 1E). 
These findings are consistent with a previous study that reported a 3–4 fold increase in 
glutamate uptake using similar conditions (Dunlop et al. 1999). While the low basal levels of 
endogenous glutamate uptake in HEK293T cells are most likely due to the activity of 
EAAT3 (Toki et al. 1998), a distinct subtype of glutamate transporter predominantly 
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localized to neurons and kidney cells (Kanai & Hediger 1992), we confirmed that the [3H]-
glutamate uptake measured for EAAT1 and EAAT2 expressing cells was sensitive to the 
glutamate transport inhibitors UCPH-101 and TBOA as described previously (Shimamoto et 
al. 2004). Comparison of the degree of pharmacological inhibition of [3H]-glutamate uptake 
by the EAAT2 specific inhibitor, DHK (10 μM) to TBOA (10 μM) in EAAT2 transfected 
cells resulted in a similar level of suppression (79 ± 3% versus 70 ± 7% respectively, data 
not shown), indicating that glutamate uptake in our heterologous expression system is 
pharmacologically regulated as expected.
We next measured the consequence of pharmacological inhibition of CaMKII on EAAT1 
and EAAT2 mediated glutamate uptake. We employed two well-established CaMKII 
inhibitors: KN-93, a small molecule inhibitor that competes with Ca2+/CaM but not ATP for 
CaMKII activation (Sumi et al. 1991, Pellicena & Schulman 2014), and tat-CN21. Inactive 
inhibitors (KN-92 and tat-CN21 Ala) were used to verify the specificity of the active 
compounds versus vehicle and other off-target effects. We observed a 34 ± 2% reduction in 
[3H]-glutamate uptake for both KN-93 and tat-CN21 in EAAT1 transfected HEK293T cells 
compared to inactive controls KN-92 and tat-CN21 Ala (Figure 2A and B). A comparable 
reduction in transfected EAAT1 activity was also observed in A172s, a glioblastoma cell 
line, following CaMKII inhibition (Supplementary Figure 1). Application of KN-93 and tat-
CN21 to naïve HEK293T cells did not alter [3H]-glutamate uptake (data not shown), 
indicating that any changes observed are not due to endogenous transporter activity, but 
rather the transfected transporter. EAAT2 mediated glutamate uptake was not altered by 
CaMKII inhibition (Figure 2B), suggesting that a general off-target effect producing reduced 
glutamate uptake is likely not caused by pharmacological manipulation (or vehicle itself). 
Thus, unlike EAAT2 mediated glutamate uptake, CaMKII inhibition selectively disrupts 
EAAT1 function.
Because previous work suggested δCaMKII is the predominant CaMKII isoform expressed 
in rodent astrocytes (Takeuchi et al. 2000), we generated a mutant variant of human 
δCaMKII (Asp136Asn) which renders CaMKII ‘dead’ owing to loss of phosphotransferase 
activity (Chao et al. 2011). Fluorescence imaging of YFP δCaMKII with mCherry EAAT1 
and EAAT2 demonstrates an overlap in expression patterns for both wild-type 
(Supplementary Figures 3A and 3B) and Asp136Asn δCaMKII (Figures 3A and 3B). 
Overexpression of Asp136Asn δCaMKII produced a 50 ± 2.9% reduction in EAAT1, but not 
EAAT2, mediated [3H]-glutamate uptake in HEK293T cells (Figures 3C and D). The most 
likely explanation for this result is that the dead CaMKII mutant protein produces a 
dominant negative phenotype, as described previously for another kinase dead variant of 
CaMKII (Kabakov & Lisman 2015). Thus, as an orthogonal approach to our 
pharmacological experiments, genetic over-expression of a dominant-negative CaMKII 
disrupts constitutive EAAT1 activity without influencing EAAT2 function.
Autophosphorylation of δCaMKII at Thr287 renders the kinase autonomously active and 
enhances CaMKII signaling independent of intracellular calcium signaling (Hudmon & 
Schulman 2002, Miller et al. 1988, Lai et al. 1987). While we observed autonomously active 
CaMKII in our cultured HEK293T cells (21.64 ± 2.3%) as measured using a kinase assay 
and the CaMKII specific substrate AC-2 (see Methods), we determined if augmenting the 
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level of autonomous activity altered EAAT1 or EAAT2 transporter function by generating a 
Thr287Asp mutant. As seen previously for the catalytically dead (Figures 3A and 3B) and 
wild-type δCaMKII (Supplementary Figures 3A and 3B), the Thr287Asp δCaMKII mutant 
displayed similar expression patterns in EAAT1 and EAAT2 transfected HEK293Ts (Figures 
4A and 4B). Surprisingly, the overexpression of Thr287Asp δCaMKII (or wild-type 
δCaMKII) did not alter [3H]-glutamate uptake by EAAT1 or EAAT2 (Figures 4C and D), 
indicating that constitutive EAAT1 (or EAAT2) glutamate uptake is not further altered by 
enhancing autonomous CaMKII levels in HEK293T cells.
To determine if EAAT1 is a substrate of CaMKII, we generated GST-fusion proteins of the 
intracellular N- and C-termini of both EAAT1 and EAAT2 in bacteria and used glutathione 
resin to capture the transporter fusions. Purified human δCaMKII was activated in a pre-
reaction to autophosphorylate Thr287 and we tested the ability of this activated CaMKII to 
phosphorylate fragments of the EAAT1 and EAAT2 transporter. Phosphorylation was 
measured by incorporation of radiolabeled phosphate into the substrates, and normalized to 
Coomassie-blue staining, to control for total protein used in each treatment. By pre-
autophosphorylating CaMKII we reduced the [γ-32P] signal produced by 
autophosphorylated CaMKII. A GST only lane served as a negative control (lane 1) while 
GluR1 (Lee et al. 1998), a subunit of the AMPA receptor, served as a positive control (lanes 
6 and 7). While we observed a weak phosphorylation signal for the N-terminus of EAAT2 
(and the C-termini of EAAT1 and EAAT2), we focused on the N-terminus of EAAT1 as it 
was both a stronger substrate (in relation to total protein) (Figure 5) and our functional data 
did not uncover any defects in EAAT2 uptake following CaMKII inhibition (Figures 2 and 
3).
As a complementary approach to our GST-fusion data, we tiled the intracellular regions of 
EAAT1 using immobilized SPOTS peptide synthesis as described previously for the voltage-
gated sodium channel Nav1.5 (Ashpole et al. 2012a) to identify if specific residues in EAAT1 
were phosphorylated by δCaMKII. The EAAT1 protein (Figure 6A) contains a sizeable N- 
and C-terminus, with a short first and third intracellular loop (the second loop was not of a 
comparable length to tile). Each 15-amino acid long peptide differed by 1 amino acid, thus 
allowing us to test the entirety of the predicted intracellular protein sequence of EAAT1 by 
creating peptides 15 amino acids long differing by only one amino acid. For example, 
peptide 1 contains residues 1–15, peptide 2 contains residues 2–16 of the N-terminus of 
EAAT1 and so on (Figure 6B). In vitro phosphorylation was quantified using 
phosphoimaging as described previously. A number of phosphorylated peptides (~peptides 
18–23) in the N-terminus of EAAT1 were observed as evidenced by an increase in [γ-32P], 
indicative of the peptides moving through a “hotspot” of CaMKII activity (Figure 6C). 
Visual inspection revealed two potential phospho-acceptor residues, Thr26 and Thr37. 
Neither the intracellular loops nor the C-terminus of EAAT1 revealed any [γ-32P] 
incorporation. CaMKII substrates GluR1 (Lee et al. 1998) and the intermediate filament 
protein vimentin (Inagaki et al. 2000) were included as positive controls of CaMKII 
phosphorylation (two bars to the far right, Figure 6C). Overall, these data are in agreement 
with the GST-fusion data (Figure 5), which indicated the EAAT1 N-terminus contained 
residues that were phosphorylated by CaMKII.
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Next, we introduced Ala substitutions for the Thr26 and Thr37 residues to identify their 
functional contribution in the context of the GST-fusions of the EAAT1 N-terminus and 
tested for phosphorylation by CaMKII in vitro. Again, Ala mutants were generated for 
Thr26 and Thr37, as well as a double Ala mutant. In vitro CaMKII phosphorylation was 
carried out as previously described. Surprisingly, Thr26Ala produced a significant increase 
in [γ-32P] incorporation. A potential reason for this phenotype could be the enhancement of 
another phosphorylation site, due to alterations in protein folding. The Thr37Ala mutant 
produced a significant reduction in [γ-32P] signal compared to wild-type (53 ± 1%), 
suggesting that this residue is phosphorylated by CaMKII. Furthermore, the double mutant 
produced a reduction that was not significant (Figure 7B, representative image in Figure 
7A). It is plausible that the double mutant is representative of the opposing effects in [γ-32P] 
incorporation of the Thr26Ala mutant and the Thr37Ala mutant, thus producing a slight but 
not significant decrease in [γ-32P] incorporation. Figure 6C, however, suggests Thr26 is a 
potential phosphorylation site of CaMKII. Due to this discrepancy, we decided to measure 
the effect of mutations at both these residues on [3H]-glutamate uptake.
To identify the functional significance of the Thr26 and Thr37 phosphorylation sites on 
EAAT1 mediated glutamate uptake, we mutated Thr26 and Thr37 into Ala residues as single 
mutants and together as a double mutant in order to mimic a non-phosphorylated state. In 
addition to these mutants, we generated single Asp (Thr26Asp and Thr37Asp to mimic 
phosphorylation) and double Asp mutants to determine the contribution of both sites. Only 
the Thr37Ala and double mutant Thr26Ala/Thr37Ala produced a significant reduction in 
[3H]-glutamate uptake (Figure 8C). Thr26 does not appear to regulate alterations in [3H]-
glutamate uptake mediated by EAAT1 as the Thr26Ala mutant did not produce any change 
in glutamate uptake. These functional changes are not due to difference in expression levels 
as immunoblots of HEK293T cells transfected with EAAT1 wild-type, Thr37Ala and 
Thr27Ala/Thr37Ala indicated that mutant variants of EAAT1 express at a similar level when 
compared to wild-type EAAT1 (Figure 8A and Figure 8B). Surprisingly, neither Thr37Asp 
nor Thr26Asp/Thr37Asp mutants increased EAAT1 mediated glutamate uptake, suggesting 
that CaMKII signaling constitutively maintains the phosphorylation state of the Thr37 
residue.
The functional linkage between the phosphorylation state of Thr37 and CaMKII signaling in 
regulating EAAT1 was evaluated by testing whether the presence of both the CaMKII 
inhibitor KN-93 and the Thr37Ala substitution were synergistic or additive when both 
manipulations were applied simultaneously. Interestingly, the Thr37Ala mutation appears to 
partially account (50%) for the reduction in glutamate uptake seen with pharmacological 
CaMKII inhibition (Figure 8D). Thus, the Thr37Ala mutation and the KN-93 effect are not 
additive, suggesting that CaMKII inhibition and mimicking the non-phosphorylation state of 
Thr37 may be functionally linked by a common mechanism.
Discussion
In this study, we demonstrate that EAAT1 and EAAT2 are differentially regulated by 
CaMKII in HEK293T cells. We observed that pharmacological inhibition of CaMKII using 
both a small molecule inhibitor KN-93 and a peptide inhibitor tat-CN21 produced a ~34–
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50% reduction in glutamate uptake mediated by EAAT1, but not EAAT2, reproducing the 
degree of inhibition previously observed in cortical astrocytes (Ashpole et al. 2013). While 
the control small molecule KN-92 as well as the inactive tat-peptide tat-CN21-Ala did not 
reduce glutamate uptake, we addressed the potential for off-target effects using a completely 
different approach. Transfection of a catalytically dead CaMKII mutant (Asp136Asn) 
produced a dominant-negative phenotype and disrupted EAAT1 function, demonstrating 
specificity for the pharmacological and genetic manipulation of CaMKII mediated 
regulation of EAAT1 function. Thus, while CaMKII activity regulates EAAT1 in our study, 
we did not observe CaMKII inhibition to influence EAAT2 mediated glutamate uptake.
Further, we demonstrate that EAAT1 is a novel CaMKII substrate in vitro, with an N-
terminal non-consensus phosphorylation site Thr37. While inhibition of CaMKII signaling 
disrupts EAAT1 glutamate uptake, upregulation of CaMKII using an “autonomous” mutant 
form of CaMKII (Thr287Asp, retains activity without Ca2+/CaM) did not alter EAAT1 
function. While it is conceivable that autonomous activity is not sufficient for EAAT1 
regulation, it is likely that basal CaMKII activity (21 ± 4% of maximal in HEK293 cells) is 
sufficient for CaMKII-mediated EAAT1 regulation in our model system.
Both SPOTS blot and GST-fusion protein data implicated Thr37 as a key residue on EAAT1 
phosphorylated by CaMKII. Generation of a non-phosphorylated Thr37Ala mutant reduced 
EAAT1 mediated glutamate uptake in a significant manner, substantiating our in vitro 
findings. Our in vitro studies also proposed Thr26 as a potential CaMKII phosphorylation 
site, however [3H]-glutamate uptake assays suggest Thr26 phosphorylation is not 
functionally relevant for constitutive EAAT1 activity. Overall, our data support the 
hypothesis that Thr37 is a CaMKII phosphorylation that is important for regulating 
glutamate uptake by EAAT1. Interestingly, the Thr37 residue we identified on EAAT1 is not 
conserved in EAAT2, potentially explaining why we did not observe CaMKII to regulate 
EAAT2. Because the non-phosphorylated Thr37Ala mutation did not reduce EAAT1 
function to the level seen with pharmacological or genetic CaMKII inhibition, we conclude 
that our experimental paradigm may have failed to uncover either additional phosphorylation 
sites and/or an alternative mechanism than contributes to EAAT1 regulation. However, it is 
important to note that while Thr37Ala mutation in EAAT1 does not produce the same level 
of glutamate transporter inhibition as seen following CaMKII inhibition, the Thr37Ala 
mutation is not synergistic or additive with KN-93 treatment, consistent with a shared 
mechanism linking the Thr37Ala mutant and reduced CaMKII signaling.
Interestingly, a number of reports suggest that GLAST (EAAT1) is the primary astrocytic 
glutamate transporter in dissociated rodent cultures, with GLT-1 (EAAT2) being expressed at 
much lower levels (Swanson et al. 1997, Gegelashvili et al. 1997), a finding that is 
substantiated in this manuscript. We find that the degree of reduction in glutamate uptake 
elicited by inhibiting CaMKII is consistent for both EAAT1 transfected HEK293Ts and 
cortical astrocytic cultures, further supporting the notion that GLAST (EAAT1) is the 
predominant transporter expressed in astrocytic cultures. Our finding that EAAT1 is 
positively regulated by CaMKII signaling and that EAAT1 itself is a CaMKII substrate is a 
novel discovery. The only splice variant of EAAT1 described to date in humans is 
EAAT1ex9skip (named so since it lacks the entirety of exon 9), and it contains the Thr37 
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residue our study implicates as being phosphorylated by CaMKII (Vallejo-Illarramendi et al. 
2005). This splice variant lacks functional glutamate uptake activity and localizes to the 
endoplasmic reticulum as a truncated protein, where it instead serves as a dominant-negative 
over full-length EAAT1. Future studies are needed to determine what the functional 
consequence of CaMKII phosphorylation of Thr37 on EAAT1ex9skip might be. In addition, 
it will be beneficial to examine the specific contribution of Thr37 phosphorylation on 
glutamate uptake within native astrocytes in future studies. We mechanistically dissected the 
regulation of this individual residue within the EAAT1 transporter using a heterologous 
expression system. While HEK293T cells are ideal to explore functional studies in 
transporter isoforms and mutant variants, future studies performed within astrocytes must be 
carefully designed and controlled to account for contaminating endogenous EAAT1 or 
EAAT2 expression.
Recent work from the Amara laboratory shows that CaMKII signaling alters trafficking of 
EAAT2b, a splice variant of EAAT2 with alterations at the C-terminus (Underhill et al. 
2015). In this study CaMKII signaling appears to be working through a scaffolding protein 
that negatively regulates EAAT2b trafficking (Underhill et al. 2015). Specifically, CaMKII 
phosphorylation of a PDZ scaffolding protein, Discs large homolog 1 (DLG1/SAP97), 
decreases surface expression of EAAT2b and presumably transporter activity. This effect 
was isoform specific, as EAAT2a trafficking was not affected by CaMKII signaling. Our 
study confirms that EAAT2a is not altered by CaMKII signaling and extends this work by 
showing that CaMKII can produce isoform specific modulation of EAAT activity. The idea 
that a kinase can differentially regulate subtypes of transporters is not unprecedented. For 
example, glycogen synthase kinase 3β has been shown to differentially modulate GLAST 
and GLT-1, producing a down-regulation in GLAST but up-regulation in GLT-1 activity and 
cell-surface expression via phosphorylation of the transporters (Jimenez et al. 2014). Future 
studies are required to determine how basal regulation of EAAT1 by CaMKII is coupled to 
EAAT2b function. Collectively, glutamate transporter regulation by CaMKII appears 
complex in that it can have opposing outcomes on transporter function that are isoform 
dependent.
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ATP Adeonosine triphosphate
BME β-mercaptoethanol
CaM Calmodulin
CaMKII Calcium/calmodulin-dependent protein kinase II
DC Detergent compatible
DIC Differential interference contrast
DMEM Dulbecco’s modified eagle’s medium
DNA Deoxyribonucleic Acid
EAAT Excitatory amino acid transporter
EDTA Ethylenediaminetetraacetic acid
EGTA Ethyleneglycoltetraacetic acid
FITC Fluorescein isothiocyanate
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GLAST Glutamate Aspartate Transporter
GLT-1 Glial glutamate transporter 1
GST Glutathione S-transferase
HEK Human embryonic kidney cell line
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
KN-92 2-[N-(4-Methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-
methylbenzylamine, monohydrochloride
KN-93 N-[2-[[[3-(4-Chlorophenyl)-2-propenyl]methylamino]methyl]phenyl]-N-(2-
hydroxyethyl)-4 -methoxybenzenesulphonamide
PBS Phosphate buffered saline
PDL poly-D-lysine
PEI Polyethylenimine
Tat HIV-1 transactivating protein
TBOA DL-threo-β-benzyoxyaspartate
Thr Threonine
RFP Red fluorescent protein
SD Standard deviation
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SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SEM Standard error of the mean
UCPH-101 2-Amino-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-
oxo-4H-chromene-3-carbonitrile
YFP Yellow fluorescent protein
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Figure 1. 
Heterologous expression of human glutamate transporters EAAT1 and EAAT2 in HEK293T 
cells. A, A representative image of mCherry EAAT1 transfected HEK293T cells viewed 
using the red channel (excit. 595 nm/emis. 620 nm) (left). A representative mCherry/DIC 
merged image is shown on the right. B, A representative image of mCherry EAAT2 
transfected HEK293T cells viewed using the red channel (left). A representative 
mCherry/DIC merged image is shown on the right. The scale bar corresponds to 100 μM in 
all panels. C, Western blot showing EAAT1 and GAPDH expression in untransfected and 
EAAT1-transfected HEK293T cells. D, Western blot showing EAAT2 and GAPDH 
expression in untransfected and EAAT2-transfected HEK293T cells. E, Average [3H]-
glutamate uptake in EAAT1 and EAAT2 transfected cells (n=3, ± S.D) normalized to 
untransfected HEK293T cells. Inhibitors UCPH-101 (10 μM) and TBOA (10 μM) were 
applied to EAAT1 and EAAT2-transfected cells respectively for 20 minutes prior to a 20 
minute [3H]-glutamate uptake measurement protocol.
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Figure 2. 
Pharmacological CaMKII inhibition reduces EAAT1 but not EAAT2 mediated [3H]-
glutamate uptake in HEK293T cells. Average [3H]-glutamate uptake in A, EAAT1 (n=6–9, 
± S.E.M) and B, EAAT2 transfected cells (n=6, ± S.D.) normalized to transfected untreated 
HEK293T cells. Inhibitors KN-93 and tat-CN21 and respective inhibitor controls KN-92 and 
tat-CN21 Ala were used at a concentration of 5 μM, and applied to cells for 20 minutes prior 
to a 20 minute [3H]-glutamate uptake measurement protocol. UCPH-101 (10 μM) and 
TBOA (10 μM) were added to EAAT1 and EAAT2 transfected cells respectively as positive 
controls. The asterisk indicates a significant difference compared to transfected untreated 
control (*, p≤0.05, one-way ANOVA, post-hoc Dunnett’s test).
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Figure 3. 
Overexpression of Asp136Asn CaMKII reduces EAAT1 but not EAAT2 mediated [3H]-
glutamate uptake in HEK293T cells. Shown is a representative image of YFP Asp136Asn 
δCaMKII in A, mCherry EAAT1 transfected and B, mCherry EAAT2 transfected HEK293T 
cells. Images are viewed using the red channel (excit. 595 nm/emis. 620 nm) (left), green 
channel (excit. 490 nm/emis. 525 nm) (center) and merged (right). Average [3H]-glutamate 
uptake in C, EAAT1 (n=6, ± S.D.) and D, EAAT2 transfected cells (n=6, ± S.D.) normalized 
to transfected untreated HEK293T cells. UCPH-101 (10 μM) and TBOA (10 μM) were 
added to EAAT1 and EAAT2 transfected cells respectively as positive controls. The asterisk 
indicates a significant difference compared to transfected untreated control vector (*, 
p≤0.05, one-way ANOVA, post-hoc Dunnett’s test).
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Figure 4. 
Overexpression of an autonomous Thr287 CaMKII autophosphorylation mutant does not 
alter EAAT1 and EAAT2 mediated [3H]-glutamate uptake in HEK293T cells. Shown are 
representative images of YFP Thr287Asp δCaMKII in A, mCherry EAAT1 transfected and 
B, mCherry EAAT2 transfected HEK293T cells. Images are viewed using the red channel 
(excit. 595 nm/emis. 620 nm) (left), green channel (excit. 490 nm/emis. 525 nm) (center) 
and merged (right). Average [3H]-glutamate uptake in C, EAAT1 (n=6, ± S.D.) and D, 
EAAT2 transfected cells (n=6, ± S.D.) normalized to transfected untreated HEK293T cells. 
UCPH-101 (10 μM) and TBOA (10 μM) were added to EAAT1 and EAAT2 transfected cells 
respectively as positive controls
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Figure 5. 
CaMKII phosphorylates a GST-fusion protein expressing the N-terminus of EAAT1. 
Representative image of [γ-32P] incorporation (top) and Coomassie gel (below) of GST-
fusion EAAT1, EAAT2 and GluR1 proteins phosphorylated by purified δCaMKII. Lanes 
contain 1: GST only, 2: GST EAAT1 N-terminus, 3: GST EAAT1 C-terminus, 4: GST 
EAAT2 N-terminus, 5: GST EAAT2 C-terminus, 6 and 7: GST GluR1.
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Figure 6. 
CaMKII phosphorylation of GST EAAT1 using SPOTS blot analysis identified two residues 
in the Nterminus, Thr26 and Thr37, that are important for phosphorylation. A, Structural 
representation of EAAT1; both the N- and C-terminus are intracellular, as well as shorter 
intracellular loops between transmembrane segments B, Schematic of the SPOTS tiling 
assay performed in C. C, Representative image of [γ-32P] incorporation in 15 amino acid 
long peptides tiling the intracellular regions of EAAT1 from the N-terminus through the C-
terminus, differing by 1 amino acid. GluR1 and vimentin served as positive controls (two 
bars to the far right).
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Figure 7. 
GST-fusion proteins suggest Thr37 is a potential phospho-site for CaMKII. A, 
Representative image of [γ-32P] incorporation (top) and Coomassie gel (below) of GST-
fusion proteins (wild-type and mutant EAAT1) phosphorylated by δCaMKII. Lanes contain 
1: GST only, 2: GST EAAT1 N-terminus wild-type, 3: GST EAAT1 N-terminus Thr26Ala, 
4: GST EAAT1 N-terminus Thr37Ala, 5: GST EAAT1 N-terminus Thr26Ala Thr37Ala, and 
6: GST GluR1. B, Average densitometry calculated as [γ-32P]/Coomassie signal (n=4± 
S.D) is demonstrated for GST-EAAT1 N-terminus mutant phosphorylation. The asterisk 
indicates significant difference compared to wild-type control (*, p≤0.05, one-way ANOVA, 
post-hoc Dunnett’s test).
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Figure 8. 
CaMKII phosphorylation of EAAT1 Thr37 regulates [3H]-glutamate uptake in transfected 
HEK293Ts. A, Representative Western blot showing EAAT1 and GAPDH expression for 
EAAT1 wild-type, Thr37Ala, and Thr26Ala/Thr37Ala-transfected HEK293T cells. B, Bar 
graph summarizing data from A (n=3, ± S.D.). C, Average [3H]-glutamate uptake in EAAT1 
wild-type, and EAAT1 mutants: Thr26Ala, Thr26Asp, Thr37Ala, Thr37Asp, Thr26Ala/
Thr37Ala, Thr26Asp/Thr37Asp (n=6, ± S.D.) normalized to transfected untreated HEK293T 
cells. D, Average [3H]-glutamate uptake in EAAT1 wild-type and EAAT1 Thr37Ala mutant, 
with application of inhibitor KN-93 (5μM) and inactive control KN-92 (5μM) for 20 minutes 
prior to a 20 minute [3H] uptake measurement protocol. The asterisk indicates significant 
difference compared to transfected untreated control (*, p≤0.05, one-way ANOVA, post-hoc 
Dunnett’s test) and the hatched bar indicates significant difference compared to transfected 
untreated control (#, p≤0.05, one-way ANOVA, post-hoc Dunnett’s test).
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